MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Esperion Therapeutics Company Profile (NASDAQ:ESPR)

Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (?)
Ratings Breakdown: 3 Hold Rating(s), 10 Buy Rating(s)
Consensus Rating:Buy (Score: 2.77)
Consensus Price Target: $63.92 (290.69% upside)

Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
Show:
DateFirmActionRatingPrice TargetActions
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$113.00 -> $67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016Chardan CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Stifel NicolausBoost Price TargetBuy$64.00 -> $105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016BarclaysLower Price TargetOverweight$76.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2015RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Needham & Company LLCReiterated RatingPositive$115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Bank of AmericaReiterated RatingBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/26/2015Lake Street CapitalInitiated CoverageBuy$94.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/26/2015WallachBeth CapitalInitiated CoverageBuy$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2015Citigroup Inc.Lower Price TargetBuy$120.00 -> $45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2015JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015Credit SuisseLower Price TargetNeutral$86.00 -> $51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/17/2015FIXReiterated RatingaddView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/29/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha